



Michael
Detke/AM/LLY@LILLY
05/05/2008 07:45 AM

To Teresa S Williams/AM/LLY@Lilly
cc
bcc
Subject Re: Withdrawal scale for Duloxetine

If you use an elicited scale, you'll see higher rates. This WILL end up in the label. Mike

Michael Detke, M.D., Ph.D.
Executive Director, Neuroscience Medical Research
Eli Lilly and Company

CONFIDENTIALITY NOTICE: This e-mail message from Eli Lilly and Company (including all attachment(s) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

-by Blackberry-

Michael Detke

----- Original Message -----

From: Michael Detke
Sent: 05/05/2008 07:44 AM EDT
To: Teresa Williams
Subject: Re: Withdrawal scale for Duloxetine

We didn't use any elicited scales.

The data that exist are nicely summarized in a Perahia paper.

Other things may have been used more recently.

I'd ask David Perahia and Jim Russell if you want to dig further.

Mike

Michael Detke, M.D., Ph.D.
Executive Director, Neuroscience Medical Research
Eli Lilly and Company

CONFIDENTIALITY NOTICE: This e-mail message from Eli Lilly and Company (including all attachment(s) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure, copying or distribution is strictly prohibited. If you are not the intended recipient, please contact the sender by reply e-mail and destroy all copies of the original message.

-by Blackberry-

Teresa S Williams

----- Original Message -----

From: Teresa S Williams
Sent: 05/05/2008 07:27 AM EDT
To: Michael Detke
Subject: Withdrawal scale for Duloxetine

Mike -

Amy Chappell suggested I send this question to you:

The iGluR5 team is looking at incorporating a withdrawal symptom checklist into our Phase 2 trials. We're thinking about utilizing the Rickel's symptom checklist, however I was asked to check with the duloxetine and atomoxetine teams to see what scale they may have utilized early in their development. Would either of you know for your respective compound what scale was used to verify that there were no discontinuation symptoms?

Would you have any clue, Mike, what was initially used in the early phase duloxetine trials? I looked in our retrospective database and didn't see anything come up as a withdrawal scale.

Teresa